ASCO GU Cancers Symposium 2018 Live Coverage

Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)


Background: The bone-targeting agents (BTAs) denosumab and bisphosphonates (BPs) are widely used in the supportive care of patients (pts) with CRPC and bone metastases. We present data on pts treated with radium-223 dichloride (Ra-223) with or without a concomitant BTA in an international EAP.

Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223.

Identifying a reliable marker of efficacy for radium-223 dichloride (Ra-223) would aid in the clinical management of mCRPC patients (pts).

Role of FSH in the musculoskeletal side effects associated with androgen deprivation therapy (ADT) for prostate cancer

Introduction: In the treatment of advanced prostate cancer, gonadotropin releasing hormone/luteinizing hormone releasing hormone (GnRH/LHRH) receptor agonists and antagonists both reduce testosterone to castrate levels.